Juvenile Macular Degeneration (Stargardt Disease) Pipeline Review, H1 2020 - ResearchAndMarkets.com

DUBLIN--()--The "Juvenile Macular Degeneration (Stargardt Disease) Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This pipeline guide Juvenile Macular Degeneration (Stargardt Disease) Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Juvenile Macular Degeneration (Stargardt Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 2, 10 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered

  1. Introduction
  2. Severe Acute Respiratory Syndrome (SARS) - Overview
  3. Severe Acute Respiratory Syndrome (SARS) - Therapeutics Development
  4. Severe Acute Respiratory Syndrome (SARS) - Therapeutics Assessment
  5. Severe Acute Respiratory Syndrome (SARS) - Companies Involved in Therapeutics Development
  6. Severe Acute Respiratory Syndrome (SARS) - Drug Profiles
  7. Severe Acute Respiratory Syndrome (SARS) - Dormant Projects
  8. Severe Acute Respiratory Syndrome (SARS) - Product Development Milestones

Companies Mentioned

  • Acucela Inc
  • Alkeus Pharmaceuticals Inc
  • Alpine Biotherapeutics Corp
  • Applied Genetic Technologies Corp
  • Astellas Pharma Inc
  • Beam Therapeutics Inc
  • Biogen Inc
  • Biophytis SA
  • Cardax Inc
  • Copernicus Therapeutics Inc
  • Generation Bio Corp
  • Grupo Ferrer Internacional SA
  • Ichor Therapeutics Inc
  • IVERIC bio Inc
  • Katairo GmbH
  • Lin Bioscience Inc
  • Mediphage Bioceuticals Inc
  • ProQR Therapeutics NV
  • Sanofi
  • Spark Therapeutics Inc
  • Stargazer Pharmaceuticals Inc
  • Vision Medicines Inc
  • Wave Life Sciences Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/fvxpp6

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900